Yes there are now several vaccines that are in use. The first mass vaccination programme started in early December 2020 and as of and as of 15 February 2021, 175.3 million vaccine doses have been administered. At least 7 different vaccines (3 platforms) have been administered.

WHO issued an Emergency Use Listing (EULs) for the Pfizer COVID-19 vaccine (BNT162b2) on 31 December 2020. On 15 February 2021, WHO issued EULs for two versions of the AstraZeneca/Oxford COVID-19 vaccine, manufactured by the Serum Institute of India and SKBio. On 12 March 2021, WHO issued an EUL for the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson). WHO is on track to EUL other vaccine products through June. 

The products and progress in regulatory review by WHO is provided by WHO and updated regularly. The document is provided here.

Once vaccines are demonstrated to be safe and efficacious, they must be authorized by national regulators, manufactured to exacting standards, and distributed. WHO is working with partners around the world to help coordinate key steps in this process, including to facilitate equitable access to safe and effective COVID-19 vaccines for the billions of people who will need them. More information about COVID-19 vaccine development is available here.

• Ihakikishwe kwamba chanjo hiyo ipo salama kwa matumizi ya binaadamu.
• Ukaguzi wa kila chanjo itakayo kuwa inatumika mara kwa mara , ukaguzi unatakiwa kufanyika ili kuhakikisha usalama  wa ki afya na maendeleo.Na ukaguzi huu unatakiwa ufanyike kwenye nchi Husika , ambapo chanjo hizo zitapatikana mpaka nchi zitakapoenda kutumika na ukaguzi huu utafanywa na shirika la WHO. 
• Pia ukaguzi wa taarifa kuhusiana na maambukizi ya Corona , hii itasaidida kutoa maelekezo ni jinsi gani kinga hii itatumika.
• Wakaguzi hawa watachaguliwa na Shirika la WHO, dhidi ya kuhakikisha maambukizi hayasambai tena kwa kiasi kikubwa na kuchunguza je ni makundi yapi yanayoathiriwa sana na maambukizi haya na je chanjo yake itumike vipi.
• Nchi husika, ina Jukumu la kuamua ni jinsi gani chanjo hizi zitatumika, kutokana na shirika la WHO, litakavyo shauri.
• Chanjo hizi zitazalishwa kwa wingi ili kuhakikisha , utoaji unafanyika kwa watu wengi ili kuokoa maisha ya binaadamu wengi .
• Na mwisho kabisa kinga na chanjo bora zote , zitasajiliwa na kusambazwa kwa wingi , ili ziweze kutumika kwa wingi na kutoa tiba kwa wingi.

The impact of COVID-19 vaccines on the pandemic will depend on several factors. These include the effectiveness of the vaccines; how quickly they are approved, manufactured, and delivered; the possible development of other variants and how many people get vaccinated

Whilst trials have shown several COVID-19 vaccines to have high levels of efficacy, like all other vaccines, COVID-19 vaccines will not be 100% effective. WHO is working to help ensure that approved vaccines are as effective as possible, so they can have the greatest impact on the pandemic.

Scientists around the world are developing many potential vaccines for COVID-19. These vaccines are all designed to teach the body’s immune system to safely recognize and block the virus that causes COVID-19.

Several different types of potential vaccines for COVID-19 are in development, including:

• Inactivated or weakened virus vaccines, which use a form of the virus that has been inactivated or weakened so it doesn’t cause disease, but still generates an immune response.
• Protein-based vaccines, which use harmless fragments of proteins or protein shells that mimic the COVID-19 virus to safely generate an immune response.
• Viral vector vaccines, which use a safe virus that cannot cause disease but serves as a platform to produce coronavirus proteins to generate an immune response.
• RNA and DNA vaccines, a cutting-edge approach that uses genetically engineered RNA or DNA to generate a protein that itself safely prompts an immune response.

For more information about all COVID-19 vaccines in development, see this WHO publication, which is being updated regularly. 

Currently, there is no evidence that any other vaccines, apart from those specifically designed for the SARS-Cov-2 virus,  will protect against COVID-19.

However, scientists are studying whether some existing vaccines – such as the Bacille Calmette-Guérin (BCG) vaccine, which is used to prevent tuberculosis – are also effective for COVID-19. WHO will evaluate evidence from these studies when available.

• Have a compromised immune system
• Are pregnant or nursing your baby
• Have a history of severe allergies, particularly to a vaccine (or any of the ingredients in the vaccine)
• Are severely frail 

Vaccination protects you from getting seriously ill and dying from COVID-19. For the first fourteen days after getting a vaccination, you do not have significant levels of protection, then it increases gradually. For a single dose vaccine, immunity will generally occur two weeks after vaccination. For two-dose vaccines, both doses are needed to achieve  are required to provide the highest level of best immunity possible. 

While a COVID-19 vaccine will protect you from serious illness and death, we still don’t know the extent to which it keeps you from being infected and passing the virus on to others. To help keep others safe, continue to maintain at least a 1-metre distance from others, cover a cough or sneeze in your elbow, clean your hands frequently and wear a mask, particularly in enclosed, crowded or poorly ventilated spaces. Always follow guidance from local authorities based on the situation and risk where you live.

Vaccines are usually tested in adults first, to avoid exposing children who are still developing and growing. COVID-19 has also been a more serious and dangerous disease among older populations. Now that the vaccines have been determined to be safe for adults, they are being studied in children. Once those studies have been completed, we should know more and guidelines will be developed.

In the meantime, make sure children continue to physical distance from others, clean their hands frequently, sneeze and cough into their elbow and wear a mask if age appropriate.

Ensuring the safety and quality of vaccines is one of WHO’s highest priorities. WHO works closely with national authorities to ensure that global norms and standards are developed and implemented to assess the quality, safety and efficacy of vaccines. 

The process to develop COVID vaccines is fast-tracked while maintaining the highest standards: Given the urgent need to stop the pandemic, pauses between steps, often needed to secure funding, have been shortened, or eliminated, and in some cases, steps are being carried out in parallel to accelerate the process, wherever that is safe to do. COVID-19 vaccine developers have issued a joint pledge not to seek government approval for their vaccines until they’ve been proven to be safe and effective. 

There are many strict protections in place to help ensure that COVID-19 vaccines are safe. Like all vaccines, COVID-19 vaccines are going through a rigorous, multi-stage testing process, including large (phase III) trials that involve tens of thousands of people. These trials, which include some groups at high risk for COVID-19 (certain groups like pregnant and lactating women were not included in vaccine trials), are specifically designed to identify any common side effects or other safety concerns.

Once a clinical trial shows that a COVID-19 vaccine is safe and effective, a series of independent reviews of the efficacy and safety evidence is required, including regulatory review and approval in the country where the vaccine is manufactured, before WHO considers a vaccine product for EUL or prequalification. EUL or Prequalification verifies to those countries that would want to procure a particular vaccine that there has been an assurance by WHO that the regulatory review process, usually in the country of manufacture, has held up to the highest standards. Part of this process also involves a review of all the safety evidence by the Global Advisory Committee on Vaccine Safety.

An external panel of experts convened by WHO analyzes the results from clinical trials, along with evidence on the disease, age groups affected, risk factors for disease, and other information.  The panel recommends whether and how the vaccines should be used. Officials in individual countries decide whether to approve the vaccines for national use and develop policies for how to use the vaccines in their country based on the WHO recommendations.

After a COVID-19 vaccine is introduced, WHO supports work with vaccine manufacturers, health officials in each country, and other partners to monitor for any safety concerns on an ongoing basis.

Ensuring the safety and quality of vaccines is one of WHO’s highest priorities. WHO works closely with national authorities to ensure that global norms and standards are developed and implemented to assess the quality, safety and efficacy of vaccines. 

The process to develop COVID vaccines is fast-tracked while maintaining the highest standards: Given the urgent need to stop the pandemic, pauses between steps, often needed to secure funding, have been shortened, or eliminated, and in some cases, steps are being carried out in parallel to accelerate the process, wherever that is safe to do. COVID-19 vaccine developers have issued a joint pledge not to seek government approval for their vaccines until they’ve been proven to be safe and effective. 

There are many strict protections in place to help ensure that COVID-19 vaccines are safe. Like all vaccines, COVID-19 vaccines are going through a rigorous, multi-stage testing process, including large (phase III) trials that involve tens of thousands of people. These trials, which include some groups at high risk for COVID-19 (certain groups like pregnant and lactating women were not included in vaccine trials), are specifically designed to identify any common side effects or other safety concerns.

Once a clinical trial shows that a COVID-19 vaccine is safe and effective, a series of independent reviews of the efficacy and safety evidence is required, including regulatory review and approval in the country where the vaccine is manufactured, before WHO considers a vaccine product for EUL or prequalification. EUL or Prequalification verifies to those countries that would want to procure a particular vaccine that there has been an assurance by WHO that the regulatory review process, usually in the country of manufacture, has held up to the highest standards. Part of this process also involves a review of all the safety evidence by the Global Advisory Committee on Vaccine Safety.

An external panel of experts convened by WHO analyzes the results from clinical trials, along with evidence on the disease, age groups affected, risk factors for disease, and other information.  The panel recommends whether and how the vaccines should be used. Officials in individual countries decide whether to approve the vaccines for national use and develop policies for how to use the vaccines in their country based on the WHO recommendations.

After a COVID-19 vaccine is introduced, WHO supports work with vaccine manufacturers, health officials in each country, and other partners to monitor for any safety concerns on an ongoing basis.

Chanjo ya corona imeshapatikana , nchi mbalimbali, lakini kabla haijapewa kibali cha kutumika kama chanjo lazima,

Ihakikishwe kama iko salama kwa matumizi.

Ukaguzi wa kila chanjo mara kwa mara ili kuhakikisha chanjo ni salama ata kwa matumizi ya kibinaadamu kuanzia kwenye nchi husika chanjo inapotengenezwa adi kutumika kwenye nchi nyengine na ukaguzi huu utafanyika na shirika la WHO.

Pia ukaguzi wa taarifa kuhusiana na maambukizi ya covid-19, ili kutoa maelekezo ni jinsi gani kinga ya corona itatumika.

Wakaguzi wakuu pia waliochaguliwa na shirika la WHO dhidi ya kuhakikisha, maambukizi hayashambulii kwa kiasi kikubwa na kufanya tafiti je ni makundi gani yana athiriwa sana na kwa kiasi gani, na ndipo SAGE watatoa ushauri juu ya matumizi ya chanjo .

Nchi husika , ina jukumu la kuamua ni jinsi gani chanjo hizi zitatumika, kutokana na sheria za shirika la WHO, litakavyotoa maelekezo.Na chanjo hizi zitazalishwa kwa wingi ili kuokoa maisha ya binaadamu wengi.

Na mwisho kabisa kinga na chanjo borazote, zitasajiliwa na kusambazwa kwa wingi, ili ziweze kutumika na kutoa tiba iliyo sahihi.

Kuna aina nyingi za chanjo, na aina hizi zote zimeshagawanyishwa tayari, na kushirikiana na shirika la WHO, chanjo hizi zinafanyiwa uchunguzi na na kuanza kutumika rasmi kama kinga na chanjo dhidi ya covid.

Vaccines are usually tested in adults first, to avoid exposing children who are still developing and growing. COVID-19 has also been a more serious and dangerous disease among older populations. Now that the vaccines have been determined to be safe for adults, they are being studied in children. Once those studies have been completed, we should know more and guidelines will be developed.

In the meantime, make sure children continue to physical distance from others, clean their hands frequently, sneeze and cough into their elbow and wear a mask if age appropriate.